UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial
UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial
在亨廷頓基因治療試驗的低劑量隊列數據公佈後，UnQure股價上漲
- UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease.
- Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.
- AMT-130 was generally well-tolerated in treated patients at the lower dose of 6x1012 vector genomes.
- No serious adverse events related to AMT-130 were reported in these patients.
- Related: Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data.
- Measurements of CSF NfL, a key biomarker of neuronal damage, increased as expected following the AMT-130 surgical procedure and approached baseline at 12 months.
- Measurements of mHTT protein in the CSF of evaluable treated patients showed decreases compared to baseline through 12 months.
- Biomarker and clinical data, including 24-month follow-up in the low-dose U.S. cohort and 12-month follow-up in the high-dose U.S. cohort expected in 1H of 2023.
- Price Action: QURE shares are 24.40% at $19.15 during the market session on the last check Thursday.
- UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease.
- Six of the ten enrolled patients received AMT-130, and four received an imitation surgical procedure in this randomized, blinded clinical trial in the U.S.
- AMT-130 was generally well-tolerated in treated patients at the lower dose of 6x1012 vector genomes.
- No serious adverse events related to AMT-130 were reported in these patients.
- Related: Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data.
- Measurements of CSF NfL, a key biomarker of neuronal damage, increased as expected following the AMT-130 surgical procedure and approached baseline at 12 months.
- Measurements of mHTT protein in the CSF of evaluable treated patients showed decreases compared to baseline through 12 months.
- Biomarker and clinical data, including 24-month follow-up in the low-dose U.S. cohort and 12-month follow-up in the high-dose U.S. cohort expected in 1H of 2023.
- Price Action: QURE shares are 24.40% at $19.15 during the market session on the last check Thursday.
- UnQure N.V.納斯達克公司(Temasek Holdings：QUURE)宣佈了正在進行的AMT-130基因療法治療亨廷頓病1/2期低劑量隊列試驗的10名患者的安全性和生物標誌物數據。
- 在美國的這項隨機、盲目臨牀試驗中，10名入選患者中有6名接受了AMT-130，4名接受了模擬外科手術。
- 在較低劑量的6×1012載體基因組治療患者中，AMT-130的耐受性通常很好。
- 在這些患者中，沒有與AMT-130相關的嚴重不良事件的報道。
- 相關： 瑞穗對UniQure即將發佈的小劑量亨廷頓基因療法試驗數據的評論.
- 腦脊液NFL是神經元損傷的關鍵生物標誌物，在AMT-130手術後，其測量結果如預期般增加，並在12個月時接近基線。
- 可評估的治療患者的腦脊液中mHTT蛋白的測量結果顯示，在12個月中與基線相比有所下降。
- 生物標記物和臨牀數據，包括低劑量美國隊列的24個月隨訪和預計2023年上半年的高劑量美國隊列12個月的隨訪。
- 價格行動：在週四最後一次檢查的市場時段，Qure的股價上漲了24.40%，至19.15美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！